{
  "prompt": [
    {
      "type": "text",
      "content": "How did actual combined revenue from Pfizerâ€™s (NYSE: PFE) Paxlovid and Comirnaty in FY 2024 compare to guidance released in Q4 2023? Report it as % BEAT or MISS, rounded to two decimal points of precision (ex: XX.XX% MISS)."
    }
  ],
  "rubrics": [
    {
      "name": "Task completion",
      "weight": 1.0,
      "score": {
        "type": "discrete",
        "outcomes": [
          {
            "label": "yes",
            "score": 1.0
          },
          {
            "label": "no",
            "score": 0.0
          }
        ]
      },
      "messages": [
        {
          "type": "text",
          "content": "[{\"operator\":\"correctness\",\"criteria\":\"Find guidance from Q4 2023 for FY 2024 combined Comirnaty and Paxlovid revenue: $8.0B\"},{\"operator\":\"correctness\",\"criteria\":\"Find actual FY 2024 Comirnaty revenue: $5,353M\"},{\"criteria\":\"Find actual FY 2024 Paxlovid revenue: $5,716M\",\"operator\":\"correctness\"},{\"operator\":\"correctness\",\"criteria\":\"Calculate the combined revenue for Comirnaty and Paxlovid: $5,716M + $5,353M = 11.069B\"},{\"criteria\":\"Compare the actual and guidance Comirnaty and Paxlovid revenues in FY 2024: (11.069B - $8.0B)/$8.0B x 100 = 38.36%\",\"operator\":\"correctness\"},{\"criteria\":\"Classify the performance as a BEAT, because the actual value is greater than the guidance value \",\"operator\":\"correctness\"},{\"operator\":\"correctness\",\"criteria\":\"Final answer includes the value \\\"38.36%\\\" as this is the percent difference between the actual and guidance revenues\"},{\"operator\":\"correctness\",\"criteria\":\"Final answer is rounded to two decimal points of precision\"}]"
        }
      ],
      "dependencies": []
    }
  ],
  "include_files": false,
  "use_docker": false
}